The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | The impact of social determinants of health on overall survival in patients with AML
Shai Shimony, MD, Dana-Farber Cancer Institute, Boston, MA, comments on the impact of social determinants of health on overall survival in patients with acute myeloid leukemia (AML). Dr Shimony notes that the impact of social determinants of health is not uniform across all genetically defined risk groups in AML, with this study revealing an association in the intermediate-risk group. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We know from previous studies that social determinants of health are very important in patient outcomes. However, whether the impact of social determinants of health is equal among all genetically defined risk groups in AML is unknown. Thus, we investigated whether the impact of social determinants of health using a national ADI index is similar across all genetic groups. We found that among patients who are treated with intensive chemotherapy, those who are defined as favorable and those who are defined as adverse, there was no impact of social determinants of health on outcome defined as overall survival...
We know from previous studies that social determinants of health are very important in patient outcomes. However, whether the impact of social determinants of health is equal among all genetically defined risk groups in AML is unknown. Thus, we investigated whether the impact of social determinants of health using a national ADI index is similar across all genetic groups. We found that among patients who are treated with intensive chemotherapy, those who are defined as favorable and those who are defined as adverse, there was no impact of social determinants of health on outcome defined as overall survival. Conversely, in the intermediate-risk group, we found that social determinants of health was an important factor that was associated with survival even after adjusting for age, clinical characteristics, and other comorbidities. When we analyzed this subgroup, we found that the impact was mainly around the pre-transplant area and the post-transplant area, and we are now investigating whether this association is related more to a higher relapse rate or to non-relapse mortality among the patients within the intermediate-risk group.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
